1. Home
  2. AKRO vs BWIN Comparison

AKRO vs BWIN Comparison

Compare AKRO & BWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • BWIN
  • Stock Information
  • Founded
  • AKRO 2017
  • BWIN 2011
  • Country
  • AKRO United States
  • BWIN United States
  • Employees
  • AKRO N/A
  • BWIN N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • BWIN Specialty Insurers
  • Sector
  • AKRO Health Care
  • BWIN Finance
  • Exchange
  • AKRO Nasdaq
  • BWIN Nasdaq
  • Market Cap
  • AKRO 3.5B
  • BWIN 2.9B
  • IPO Year
  • AKRO 2019
  • BWIN 2019
  • Fundamental
  • Price
  • AKRO $40.48
  • BWIN $44.69
  • Analyst Decision
  • AKRO Strong Buy
  • BWIN Buy
  • Analyst Count
  • AKRO 9
  • BWIN 8
  • Target Price
  • AKRO $76.29
  • BWIN $44.43
  • AVG Volume (30 Days)
  • AKRO 938.9K
  • BWIN 685.6K
  • Earning Date
  • AKRO 05-09-2025
  • BWIN 05-06-2025
  • Dividend Yield
  • AKRO N/A
  • BWIN N/A
  • EPS Growth
  • AKRO N/A
  • BWIN N/A
  • EPS
  • AKRO N/A
  • BWIN N/A
  • Revenue
  • AKRO N/A
  • BWIN $1,389,037,000.00
  • Revenue This Year
  • AKRO N/A
  • BWIN $13.39
  • Revenue Next Year
  • AKRO N/A
  • BWIN $13.65
  • P/E Ratio
  • AKRO N/A
  • BWIN N/A
  • Revenue Growth
  • AKRO N/A
  • BWIN 13.99
  • 52 Week Low
  • AKRO $17.86
  • BWIN $26.08
  • 52 Week High
  • AKRO $58.40
  • BWIN $55.82
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 36.69
  • BWIN 58.50
  • Support Level
  • AKRO $41.84
  • BWIN $44.04
  • Resistance Level
  • AKRO $45.38
  • BWIN $46.57
  • Average True Range (ATR)
  • AKRO 1.98
  • BWIN 1.80
  • MACD
  • AKRO -0.40
  • BWIN 0.40
  • Stochastic Oscillator
  • AKRO 16.39
  • BWIN 70.61

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About BWIN The Baldwin Insurance Group Inc. Class A Common Stock

The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.

Share on Social Networks: